Reuters logo
1 个月前
BRIEF-Enanta announces that AbbVie receives CHMP positive opinion for MAVIRET
2017年6月23日 / 中午11点50分 / 1 个月前

BRIEF-Enanta announces that AbbVie receives CHMP positive opinion for MAVIRET

1 分钟阅读

June 23 (Reuters) - Enanta Pharmaceuticals Inc

* Enanta announces that abbvie receives chmp positive opinion for maviret™ (glecaprevir/pibrentasvir) for the treatment of chronic hepatitis c in all major genotypes (gt1-6)

* Enanta announces that abbvie receives chmp positive opinion for maviret™ (glecaprevir/pibrentasvir) for the treatment of chronic hepatitis c in all major genotypes (gt1-6)

* Says ‍final european commission decision expected q3 2017​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below